BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24970311)

  • 1. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects.
    Abdel-Rahman O
    Crit Rev Oncol Hematol; 2015 Jan; 93(1):18-27. PubMed ID: 24970311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramucirumab for gastric cancer.
    Shitara K; Ohtsu A
    Expert Rev Gastroenterol Hepatol; 2015 Feb; 9(2):133-9. PubMed ID: 25431958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor a inhibition in gastric cancer.
    Park DJ; Thomas NJ; Yoon C; Yoon SS
    Gastric Cancer; 2015 Jan; 18(1):33-42. PubMed ID: 24993497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging mAbs for the treatment of esophagogastric cancer.
    Ku GY; Ilson DH
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):63-74. PubMed ID: 25483267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab: successfully targeting angiogenesis in gastric cancer.
    Javle M; Smyth EC; Chau I
    Clin Cancer Res; 2014 Dec; 20(23):5875-81. PubMed ID: 25281695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy in gastric cancer.
    Thiel A; Ristimäki A
    APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramucirumab and its use in gastric cancer treatment.
    Bronte G; Galvano A; Cicero G; Passiglia F; Rolfo C; Bazan V; Russo A
    Drugs Today (Barc); 2014 Sep; 50(9):613-21. PubMed ID: 25313368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.
    Roviello G; Petrioli R; Marano L; Polom K; Marrelli D; Perrella A; Roviello F
    Gastric Cancer; 2016 Jan; 19(1):31-41. PubMed ID: 26329368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy in advanced gastric carcinoma: the future is beginning.
    Schinzari G; Cassano A; Orlandi A; Basso M; Barone C
    Curr Med Chem; 2014; 21(8):1026-38. PubMed ID: 24304282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
    Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
    Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
    Van Cutsem E; de Haas S; Kang YK; Ohtsu A; Tebbutt NC; Ming Xu J; Peng Yong W; Langer B; Delmar P; Scherer SJ; Shah MA
    J Clin Oncol; 2012 Jun; 30(17):2119-27. PubMed ID: 22565005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New targeted therapies for gastric cancer.
    Asaoka Y; Ikenoue T; Koike K
    Expert Opin Investig Drugs; 2011 May; 20(5):595-604. PubMed ID: 21406037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.
    Abdel-Rahman O
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):235-45. PubMed ID: 25353620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
    Li H; Adachi Y; Yamamoto H; Min Y; Ohashi H; Ii M; Arimura Y; Endo T; Lee CT; Carbone DP; Imai K; Shinomura Y
    Cancer; 2011 Jul; 117(14):3135-47. PubMed ID: 21264842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecularly targeted therapies in advanced gastric cancer.
    Janjigian YY; Shah MA
    Minerva Gastroenterol Dietol; 2011 Mar; 57(1):75-88. PubMed ID: 21372772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
    Kim J; Hwang J; Jeong H; Song HJ; Shin J; Hur G; Park YW; Lee SH; Kim J
    Epigenetics; 2012 Feb; 7(2):191-200. PubMed ID: 22395469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis inhibitors in early development for gastric cancer.
    Pinto MP; Owen GI; Retamal I; Garrido M
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1007-1017. PubMed ID: 28770623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
    Smyth EC; Tarazona N; Chau I
    Immunotherapy; 2014; 6(11):1177-86. PubMed ID: 25496333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular targeting agents for advanced or recurrent gastric cancer patients].
    Fuse N
    Nihon Rinsho; 2012 Oct; 70(10):1819-26. PubMed ID: 23198568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research status quo and progression in targeted therapy for advanced gastric cancer].
    Feng R; Zhang X; Yang S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Oct; 19(10):1191-1196. PubMed ID: 27781258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.